Clinical trial · Interventional
Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
A Prospected Randomized Multicenter Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
NCT01669369CI-TRIAL-00024537Li2CO3unknownPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether Lithium Carbonate combined with neo-adjuvant chemotherapy improve the prognosis of osteosarcoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lithium Carbonate | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
- The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
- interventionNames
- Drug: Placebo
- type
- EXPERIMENTAL
- label
- Lithium Carbonate
- description
- Patients in this arm take Lithium Carbonate twice a day with a dose of 20-25mg/kg/d.
- interventionNames
- Drug: Lithium Carbonate
Primary outcomes (1)
- measure
- progression-free survival,incidence of chemotherapy-induced myelosuppression
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 8 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * histologically diagnosed primary classical osteosarcoma in extremities * staging IIB * MRI showing no skip lesion * receive standard neo-adjuvant chemotherapy, adjuvant chemotherapy,and standard surgical treatment Exclusion Criteria: * a history of non-standard treatment(chemotherapy or surgery) * secondary osteosarcoma or well-differentiated parosteal osteosarcoma * evident dysfunction of cardia,liver and kidney, or pregnant women or women during lactation
References
Publications (1)
- DERIVEDHattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14. PMID 31401903